• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Acute generalized exanthematous pustulosis to a novel oral anticoagulant (apixaban)
Non-vitamin K antagonist oral anticoagulants or novel oral anticoagulants (NOACs) are increasingly used in the prevention of stroke in atrial fibrillation and in the prevention and treatment of venous thromboembolism (VTE). NOACs include direct thrombin inhibitor dabigatran and factor Xa inhibitors apixaban, edoxaban and rivaroxaban. Severe cutaneous adverse reactions are rare with definite cases of drug reaction with eosinophilia and systemic symptoms (DRESS) attributed to both rivaroxaban and apixaban1,2.
Source: Annals of Allergy, Asthma and Immunology - August 2, 2021 Category: Allergy & Immunology Authors: Suran L Fernando, Jamma Li, Chris Toon, Chris Weir Source Type: research

Delayed hypersensitivity reactions to edoxaban
Edoxaban is the fourth approved Direct Oral AntiCoagulant (DOAC) that has been introduced into the European market (2015), after dabigatran (2008), rivaroxaban (2008) and apixaban (2011). Dabigatran is the only direct thrombin inhibitor, whereas apixaban, edoxaban, and rivaroxaban are factor-Xa inhibitors. In a few years DOACs' use steadily increased in clinical practice for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) [1], as well as for treatment and prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE)[2].
Source: Annals of Allergy, Asthma and Immunology - August 27, 2020 Category: Allergy & Immunology Authors: Laura Franceschini, Giulia Carli, Giancarlo Landini, Daniela Matarrese, Alessandro Farsi Tags: Letters Source Type: research

Clinical pre ‐test of a computerised antithrombotic risk assessment tool for stroke prevention in atrial fibrillation patients: giving consideration to NOACs
ConclusionsAccording to this decision support tool, both warfarin and NOACs are viable treatment options in majority of the patients, but there is a scope for better rationalization of therapy.
Source: Journal of Evaluation in Clinical Practice - June 6, 2016 Category: Journals (General) Authors: Yishen Wang, Beata Bajorek Tags: Original Article Source Type: research

Clinical pre‐test of a computerised antithrombotic risk assessment tool for stroke prevention in atrial fibrillation patients: giving consideration to NOACs
ConclusionsAccording to this decision support tool, both warfarin and NOACs are viable treatment options in majority of the patients, but there is a scope for better rationalization of therapy.
Source: Journal of Evaluation in Clinical Practice - May 31, 2016 Category: Journals (General) Authors: Yishen Wang, Beata Bajorek Tags: Original Article Source Type: research

New reversal agent for factor Xa inhibitors shows promise
Commentary on: Siegal DM, Curnette JT, Connolly SJ, et al.. Andexanet alfa for the reversal of Factor Xa inhibitor activity. N Engl J Med 2015;373:2413–24. Context Direct oral anticoagulants (DOACs) have emerged as alternatives to vitamin K-antagonists (eg, warfarin) for the long-term management of stroke prevention for non-valvular atrial fibrillation or venous thromboembolic disease. Favourable side-effect profiles and absence of therapeutic monitoring are important benefits of these newer agents. Warfarin is readily reversed with fresh frozen plasma (FFP) or prothrombin complex concentrates.1 The first reversal ag...
Source: Evidence-Based Medicine - May 22, 2016 Category: Internal Medicine Authors: Ghadimi, K., Welsby, I. J. Tags: Clinical trials (epidemiology), Immunology (including allergy), Drugs: cardiovascular system, Stroke, Venous thromboembolism, Unwanted effects / adverse reactions Therapeutics/Prevention Source Type: research

An Aspirin a Day: Is the Benefit Worth the Risk?
Studies have shown that aspirin, the age old remedy for pain and fever, also thins the blood. Because of this property, it can also help to lower the chances of a heart attack or a stroke caused by a blood clot in the brain. And, although research has found that it only works in certain people (specifically, those with a history of heart attack or stroke) many Americans are inappropriately taking daily, low doses of aspirin as a preventative measure. In fact, researchers have found that about 12 percent of the of nearly 69,000 U.S. adults taking aspirin on a long-term basis should not have received the prescription in the ...
Source: Healthy Living - The Huffington Post - March 13, 2015 Category: Consumer Health News Source Type: news

Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: Findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry
Conclusions: Contraindications to OAC therapy among patients with AF are common but subjective. Many patients with reported contraindications were receiving OAC, suggesting that the perceived benefit outweighed the potential harm posed by the relative contraindication.
Source: American Heart Journal - January 6, 2014 Category: Cardiology Authors: Emily C. O'Brien, DaJuanicia N. Holmes, Jack E. Ansell, Larry A. Allen, Elaine Hylek, Peter R. Kowey, Bernard J. Gersh, Gregg C. Fonarow, Christopher R. Koller, Michael D. Ezekowitz, Kenneth W. Mahaffey, Paul Chang, Eric D. Peterson, Jonathan P. Piccini, Tags: Electrophysiology Source Type: research